Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Research & Development (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Research & Development for 9 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 11.02% year-over-year to $16.8 million, compared with a TTM value of $62.1 million through Dec 2025, up 12.98%, and an annual FY2025 reading of $62.1 million, up 12.98% over the prior year.
  • Research & Development was $16.8 million for Q4 2025 at Puma Biotechnology, up from $15.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $20.2 million in Q1 2021 and bottomed at $7.0 million in Q3 2022.
  • Average Research & Development over 5 years is $14.4 million, with a median of $13.8 million recorded in 2022.
  • The sharpest move saw Research & Development tumbled 62.84% in 2022, then skyrocketed 63.51% in 2023.
  • Year by year, Research & Development stood at $14.2 million in 2021, then fell by 2.71% to $13.8 million in 2022, then fell by 6.61% to $12.9 million in 2023, then rose by 17.84% to $15.2 million in 2024, then grew by 11.02% to $16.8 million in 2025.
  • Business Quant data shows Research & Development for PBYI at $16.8 million in Q4 2025, $15.9 million in Q3 2025, and $15.5 million in Q2 2025.